In the randomized WHI trials, yes, the two regimens moved in opposite directions.
Estrogen-alone, used only in women without a uterus, was associated with lower breast cancer incidence and lower breast cancer death over more than 20 years of follow-up. Combined estrogen-progestin therapy, used in women with a uterus because estrogen alone raises the risk of uterine cancer without a progestogen, was associated with higher incidence, though the trial authors caution the estrogen-alone finding does not mean estrogen should be used specifically to lower breast cancer risk, since the benefit was concentrated in women without benign breast disease or a family history. Large observational studies, unlike the randomized estrogen-alone trial, have found estrogen-only therapy still carries somewhat higher risk with longer duration, so this is not fully settled.
The randomized trial and the largest observational meta-analysis disagree about estrogen-only therapy: the trial shows a protective effect, the observational pooled data show a modest risk increase with longer use. Both are large, careful studies, and the field has not resolved the conflict.
What the research shows, and which source each finding rests on
The estrogen-alone WHI trial, at more than 20 years of cumulative follow-up, found lower invasive breast cancer incidence (HR 0.78, P=.005) and lower breast cancer mortality (HR 0.60, P=.04) compared with placebo.
Combined estrogen-progestin therapy showed higher breast cancer incidence at 20-plus years (HR 1.28, P<.001); the trial authors caution the estrogen-alone benefit was concentrated in women without benign breast disease or family history, and that the data do not support use of estrogen for breast cancer risk reduction.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
the estrogen-alone protective effect is real and biologically plausible
Avrum Bluming, Kelly Casperson, Corinne Menn, Sharon Malone, Mary Claire Haver
The finding reproduced across both an 11.8-year and a 20-plus-year follow-up of the same randomized trial, on both incidence and mortality, a stronger design than an observational cohort, and it fits a biological model where estrogen can trigger cell death in breast tissue long deprived of it.
the finding is real in that specific trial population but not generalizable as estrogen protects the breast
the WHI writing group and the observational meta-analysis authors
The trial population was hysterectomized, older, and heavier than typical hormone therapy initiators, the benefit concentrated in a subgroup, and the largest observational meta-analysis of estrogen-only use found the opposite direction with longer duration.
What would settle it: Dose-timing studies of estradiol, rather than the specific conjugated equine estrogen used in WHI, started early in menopause with breast cancer endpoints; none currently exist.
What is really going on here
- Do I have a uterus? If not, why would the combined-therapy breast cancer numbers apply to me at all?
- Is the evidence I'm hearing about estrogen-only therapy from the randomized trial or from observational data, since they point different directions?
Questions for your doctor
- Given whether or not I have a uterus, which type of hormone therapy applies to me?
- Do I have benign breast disease or a family history that would change how this evidence applies to me?
- How would you weigh the trial data against the observational data for someone in my situation?
Questions with no answer yet
Why does the randomized estrogen-only trial show a protective effect on breast cancer while the largest observational meta-analysis of estrogen-only use shows a modest increase with longer duration, and which one is closer to the truth for a woman starting therapy today?
Partly studiedWhat is known: The randomized trial found lower breast cancer incidence and mortality with estrogen alone, reproduced across two follow-up points over 20-plus years. A large observational meta-analysis found the opposite direction with longer duration of use, and neither study design has been shown to be simply wrong.
What would test it: Dose-timing studies of estradiol started early in menopause, with breast cancer endpoints prespecified, in a population that better matches typical hormone therapy starters than the trial's older, hysterectomized cohort.
Is there a biological mechanism that would make estrogen protective in some breast tissue and harmful in other breast tissue, or is the conflicting data simply a case of two different study designs measuring different things?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: One proposed mechanism is that estrogen can trigger cell death in breast tissue long deprived of it, a biologically plausible explanation for the trial's protective finding, but this mechanism has not been directly tested against the observational finding of increased risk with longer use.
What would test it: Mechanistic studies examining how duration of estrogen deprivation before treatment affects breast tissue response to reintroduced estrogen.
Sources
- 1.Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.Chlebowski RT et al., JAMA 2020 · Randomised trial
- 2.Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.Anderson GL et al., Lancet Oncol 2012 · Randomised trial
- 3.Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 2019 · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- Does hormone therapy cause breast cancer?
- What does it actually mean that hormone therapy increases breast cancer risk by 26 percent?
- Was the WHI hormone therapy trial stopped because women were dying of breast cancer?
- Is bioidentical or micronized progesterone safer for breast cancer risk than the older synthetic progestins?
- Can breast cancer survivors take hormone therapy for their menopause symptoms?
- Is vaginal estrogen safe if I've had breast cancer, especially if I'm on an aromatase inhibitor?
- Back to topic: Hormone therapy and breast cancer